

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this joint announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this joint announcement.



**UNITED GENE HIGH-TECH
GROUP LIMITED**

聯合基因科技集團有限公司

*(Incorporated in the Cayman Islands and
continued in Bermuda with limited liability)*

(Stock Code: 399)



**EXTRAWELL PHARMACEUTICAL
HOLDINGS LIMITED**

精優藥業控股有限公司*

(Incorporated in Bermuda with limited liability)

(Stock Code: 858)

JOINT ANNOUNCEMENT/VOLUNTARY ANNOUNCEMENT

RESULTS OF CLINICAL TRIAL ON ORAL INSULIN ENTERIC-COATED SOFT CAPSULES

This is a voluntary announcement jointly made by United Gene High-Tech Group Limited (“**United Gene**”) and Extrawell Pharmaceutical Holdings Limited (“**Extrawell**”).

The board of directors of United Gene (“**United Gene Board**”) and the board of directors of Extrawell (“**Extrawell Board**”) are pleased to jointly announce that, Fosse Bio-Engineering Development Limited, an indirect non-wholly owned subsidiary of United Gene and an associate company of Extrawell, has recently completed the multi-centered, randomized, crossover and self-controlled clinical trial (the “**Clinical Trial**”) of its oral insulin enteric-coated soft capsules (the “**Medicine**”) on Type-2 diabetes. The Clinical Trial was conducted with reference to recombinant insulin glargine injection as the control drug (the “**Control Drug**”), and by way of multi-centered, randomized, crossover and self-controlled research method.

Pursuant to the results of the Clinical Trial, it is shown that there is no statistical difference between the trial group using the Medicine (the “**Trial Group**”) and the control group using the Control Drug (the “**Control Group**”) in terms of the key indicators of efficacy in both the full analysis set (FAS) and per protocol set (PPS) analysis. Indicator of efficacy of the Trial Group represents improvement statistically, in particular the average blood glucose lowering

* *For identification purpose only*

magnitude when tested with an empty stomach and after meals is greater when compared between the magnitude pre-treatment and post-treatment, reflecting that the blood glucose lowering effect of the Trial Group is not only comparable, but also demonstrated a tendency of superiority in efficacy, to the Control Group. In the other words, the Clinical Trial indicates that the Medicine do have glucose lowering and non-inferiority effect statistically.

In addition, upon treatment being observed during Clinical Trial, the Clinical Trial results showed no statistical difference of any clinical change between the Trial Group and the Control Group in terms of physical indicators and other laboratory parameters, illustrating that the Medicine was safe. In terms of any negative effects, no serious negative effect had shown in either the Trial Group or the Control Group, and the frequency of occurrence of any negative effect between the two groups was not of statistical significance, which further illustrates the safety of the Medicine.

Based on the results of the Clinical Trial, the Medicine was shown to have a clear blood glucose lowering effect, demonstrating that the effect of the Medicine is not a placebo effect, and a significant non-inferiority effect. Later on, sampler size will be enlarged in the extended clinical trial, and the clinical effect of the Medicine will continue to be further examined and confirmed in due course.

Further announcements regarding the progress of the clinical trial of the Medicine will be made as and when appropriate. Shareholders of United Gene and Extrawell and public investors should exercise caution when dealing in the shares of United Gene and Extrawell.

By Order of the Board	By Order of the Board
United Gene High-Tech Group Limited	Extrawell Pharmaceutical Holdings Limited
Lee Nga Yan	Xie Yi
<i>Executive Director</i>	<i>Chairman</i>

Hong Kong, 16 April 2015

As at the date of this joint announcement, United Gene Board comprises Ms. Lee Nga Yan, Dr. Guo Yi and Mr. Tang Rong as the executive directors, Ms. Jiang Nian (chairman), Ms. Xiao Yan and Ms. Wu Yanmin as the non-executive directors and Ms. Chen Weijun, Dr. Zhang Zhihong and Mr. Wang Rongliang as the independent non-executive directors.

As at the date of this joint announcement, Extrawell Board comprises Dr. Xie Yi (chairman), Dr. Lou Yi, Mr. Cheng Yong, Ms. Wong Sau Kuen and Mr. Liu Kwok Wah as the executive directors and Mr. Fang Lin Hu, Mr. Xue Jing Lun and Ms. Jin Song as the independent non-executive directors.